Therapy News and Research

RSS

Aethlon Medical to present data on HVC patients treated with its Hemopurifier at the 42nd ASN meeting

Aethlon Medical, Inc. disclosed today that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier® will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN).

15 Oct 2009

Overview of innovative technology for treating ischemic and autoimmune disorders

Pluristem Therapeutics Inc. today announced that it will present at the New England-Israel Life Sciences Summit at the Brandeis International Business School in Waltham, Mass. Zami Aberman, chairman and CEO of Pluristem will present an update on the company and an overview of its technology at 9:40 EDT, Oct 27, 2009.

15 Oct 2009

Prometheus Laboratories introduces three new cancer diagnostic products

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the nationwide commercial launch of three new cancer diagnostic products: ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx. Each of these tests is based on recently developed, highly sensitive microRNA technology.

15 Oct 2009

Baxter International announces financial results for third quarter 2009; updates full-year financial outlook

Baxter International Inc. today reported solid financial results for the third quarter of 2009, and provided its fourth quarter and updated full-year 2009 financial outlook.

From Baxter International Inc. 15 Oct 2009

IMS Health introduces IMS MIDAS Global Biologics

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the launch of IMS MIDAS Global Biologics™, a powerful offering that enables the company’s clients to make more confident decisions as they assess opportunities in the fast-growing, $120 billion worldwide biologics market.

15 Oct 2009

ATS Medical to exhibit its innovative cardiac surgery products at the EACTS meeting

ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services announced a number of professional educational opportunities that will focus on ATS Medical products at the upcoming European Association for Cardio-Thoracic Surgeons (EACTS) meeting.

15 Oct 2009

Negative symptoms represent an attractive target for drug development

A half-day workshop on issues in the design of clinical trials to evaluate treatments for negative symptoms of schizophrenia, chaired by Stephen Marder, MD, UCLA Department of Psychiatry and David Daniel, M.D., United BioSource Corporation was held 5 October 2009, as part of the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference in San Diego, CA.

15 Oct 2009

Patients on statin drugs may have lower AAA surgery costs

Patients taking cholesterol-lowering statin drugs may have better results and lower procedure costs when having a common operation for repairing a bulging aorta, according to a new study presented at the 95th annual Clinical Congress of the American College of Surgeons.

15 Oct 2009

National Biological to market Quantel's 308 Excimer System in the U.S.

Quantel SA (Euronext: QUA), a leading manufacturer of solid state lasers, announced today that it has entered into a Distribution Agreement with National Biological, a leading researcher and developer of light-based systems for medical and cosmetic treatments, for Quantel's 308 Excimer System for monochromatic UVB treatment of psoriasis and vitiligo in the United States.

15 Oct 2009

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

HTDS - The issuer's Serbia based operating subsidiary Slavica BioChem www.slavicabiochem.com brings attention to its Mindup Bioresearch cancer project working on molecular origins of lung cancer: prospects for personalized prevention and therapy. On October 8 2009, the company posted a filing on Pink Sheets titled MindUp Cancer Project.

15 Oct 2009

Genes to determine which rectal cancer patient can avoid surgical procedure for treatment

A set of 87 genes one day may be used to routinely determine which patients can be successfully treated for advanced rectal cancer without undergoing a surgical procedure, researchers announced at the 2009 Clinical Congress of the American College of Surgeons.

15 Oct 2009

PIKAMAB obtains U.S. patent rights to develop theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it has secured exclusive rights to two issued U.S. patents from Hospital for Special Surgery, New York. PIKAMAB is developing Lupus TherasightTM, a novel theragnostic product that will eventually help guide the drug development process and patient treatment protocols in the areas of lupus and lupus nephritis.

15 Oct 2009

Research to investigate and improve patient adherence to prescription drug therapies

CVS Caremark is sponsoring research to investigate patient adherence to prescription drug therapies and identify ways to increase adherence. Working with researchers from Harvard and Brigham and Women's Hospital, the company expects knowledge gained from the research will help health professionals better understand patient behavior and lead to developing programs that health care providers and pharmacies can use to improve medication adherence and ultimately help improve patient care and medical outcomes by avoiding costly hospital treatment.

15 Oct 2009

Policymakers urged to preserve access to advanced imaging in final health care reform legislation

Survivors and patients with cancers and heart disease, along with patient advocate organizations and physicians, today urged policymakers to enhance early diagnosis of deadly diseases by preserving access to advanced imaging, such as MRI and CT scans, in final health care reform legislation.

15 Oct 2009

Depression becomes more difficult to treat the longer it goes undiagnosed or undertreated

A new survey of 2,001 adults living with depression revealed that despite being diagnosed for an average of 12 years, many unknowingly took actions that could have sabotaged their chances of getting well. Furthermore, on average, it took about six years for respondents to seek diagnosis from a health care professional, suggesting these adults may have been coping with depression for as long as 18 years.

15 Oct 2009

UNICEF and WHO call for an urgent plan to control diarrheal disease

The United Nations Children’s Fund (UNICEF) and World Health Organization (WHO) released a joint report today demonstrating the urgent need to focus attention on diarrheal disease, a neglected illness responsible for the deaths of about 1.5 million children under 5 each year. This unacceptable loss of life can be stopped.

15 Oct 2009

NHC Geriatric Clinical Residency Program receives accreditation

National HealthCare Corporation, one of the nation’s leading operators of long-term health care and assisted living facilities, announced today that the NHC Geriatric Clinical Residency Program (GCRP) for Physical Therapists has successfully received accreditation through the American Physical Therapy Association.

15 Oct 2009

Nephrologists should weigh the benefits of dialysis over more conservative therapies for frail elders

Kidney specialists should weigh the potential quality of life for frail elders with end-stage renal disease (ESRD) in opting for dialysis over more conservative therapies, a nephrologist and a palliative care specialist suggest in an editorial in the New England Journal of Medicine.

15 Oct 2009

NICoE to study how brain works after sustaining combat-related injury using Elekta Neuromag

Projected to open in mid 2010, the National Intrepid Center of Excellence (NICoE) is a facility dedicated to the study and care of military personnel and veterans suffering from traumatic brain injury (TBI) and psychological health issues. Using Elekta Neuromag®, an advanced magnetoencephalography (MEG) device, NICoE plans to shed light on how the brain works after sustaining combat-related injury.

From Elekta 15 Oct 2009

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of less than or equal to 7 percent compared to either component alone.

15 Oct 2009

Therapy News and Research

Aethlon Medical to present data on HVC patients treated with its Hemopurifier at the 42nd ASN meeting

Overview of innovative technology for treating ischemic and autoimmune disorders

Prometheus Laboratories introduces three new cancer diagnostic products

Baxter International announces financial results for third quarter 2009; updates full-year financial outlook

IMS Health introduces IMS MIDAS Global Biologics

ATS Medical to exhibit its innovative cardiac surgery products at the EACTS meeting

Negative symptoms represent an attractive target for drug development

Patients on statin drugs may have lower AAA surgery costs

National Biological to market Quantel's 308 Excimer System in the U.S.

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

Genes to determine which rectal cancer patient can avoid surgical procedure for treatment

PIKAMAB obtains U.S. patent rights to develop theragnostic product

Research to investigate and improve patient adherence to prescription drug therapies

Policymakers urged to preserve access to advanced imaging in final health care reform legislation

Depression becomes more difficult to treat the longer it goes undiagnosed or undertreated

UNICEF and WHO call for an urgent plan to control diarrheal disease

NHC Geriatric Clinical Residency Program receives accreditation

Nephrologists should weigh the benefits of dialysis over more conservative therapies for frail elders

NICoE to study how brain works after sustaining combat-related injury using Elekta Neuromag

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News